Keensight-backed Biovian and 3P Biopharmaceuticals Merge to Form 3PBIOVIAN

BYG4lab to Acquire Finbiosoft with Support from Keensight Capital

March 14, 2024

Software

BYG4lab has signed an exclusivity agreement to acquire Finbiosoft, a Finland-based provider of quality and laboratory software for medical laboratories, with the support of Keensight Capital. The deal is intended to broaden BYG4lab's product capabilities, add Finbiosoft's technical team, and expand the group's geographic footprint across Europe and into the United States while enabling cross-selling to an expanded client base.

Cinven Acquires Majority Stake in BioAgilytix; Cobepa Reinvests

December 20, 2021

Healthcare Services

International private equity firm Cinven has agreed to acquire a majority stake in BioAgilytix through a recapitalization, with current investor Cobepa remaining a significant minority investor. GHO Capital has realised its investment and will exit; the transaction will provide funding to support BioAgilytix’s international expansion, capacity and capability investments, and buy-and-build strategy in large-molecule bioanalytical services. BioAgilytix is headquartered in Durham, North Carolina and employs about 870 staff across the United States, Europe and Australia.

Riverside Partners Combines Sequoia Biotech Consulting and Syner-G BioPharma Group

September 18, 2024

Healthcare Services

Boston-based private equity firm Riverside Partners has combined two of its portfolio companies, Sequoia Biotech Consulting and Syner-G BioPharma Group, into a single, integrated life‑sciences services business. The combined organization — bringing together regulatory, development, quality, and operational capabilities — has approximately 500 employees and will provide end-to-end solutions to pharmaceutical, biotechnology, and medical device clients.

BioCina and NovaCina Merge to Create Integrated Global CDMO

January 13, 2025

Pharmaceuticals

BioCina and NovaCina announced a strategic merger that will combine BioCina's process development and manufacturing capabilities in Adelaide with NovaCina's sterile fill-finish facility in Perth. The combined company will retain the BioCina name and provide an end-to-end CDMO offering for small molecules and biopharmaceuticals, backed by parent Bridgewest Group.

Biosynth Acquires celares to Expand Bioconjugation and Polymer Drug Delivery Capabilities

July 11, 2023

Biotechnology

Biosynth, a Switzerland-based supplier of critical raw materials and manufacturing services, acquired Berlin-based celares, a developer and manufacturer of bioconjugates, activated PEGs and polymer-based drug delivery excipients. The acquisition strengthens Biosynth's capabilities in conjugate vaccines and bioconjugate drugs and adds GMP bioconjugation and PEGylation manufacturing in Berlin to its service offering.

Keensight Capital Acquires Majority Stake in Isto Biologics

September 22, 2025

Medical Devices

Keensight Capital has acquired a majority stake in Isto Biologics, a US-based regenerative MedTech company focused on orthobiologic bone graft solutions. Thompson Street Capital Partners will retain a minority stake alongside Isto's management; Keensight plans to support Isto's international expansion and pursue additional acquisitions to accelerate growth.